The efficacies of macrolide antibiotics, rokitamycin, leukomycin, josamycin and erythromycin were investigated against 63 strains of
M. pneumoniae included FH strain which were isolated from clinical specimens obtained in 1986-1987, 1991, 1992-1993. Values of MICs and MBCs of these antibiotics were evaluated by two methods, broth dilution method and
M. pneumoniae L cell infection system. In broth dilution method, MIC
50and MBC
50of rokitamycin were 0.0063-0.025μg/ml and 0.025-0.2 μg/ml respectively. The ratios of MBC
50/MIC
50 were 1-32. MIC
50 of leukomycin, josamycin and erythromycin were 0.0063-0.05μg/ml, 0.0025-0.05, ug/ml, and 0.0125-0.05μg/ml respectively. MBC
50 of these drugs were 0.0125-50μg/ml, 25-50μg/ml, and 25-50μg/ml respectively. The ratios of MIC5O/MBC
50 were 2-800, 500-2000, 500-4000. MIC
50 of rokitamycin and leukomycin to the isolates during period from 1992-1993 were higher as compare to those of isolates during 1986 to 1991.
On the other hand, rokitamycin markedly reduced the numbers of CFU in the growth phase when added at the concentrations of 16 and 4 times the MIC, but the other macrolides were reduced slightly CFU at the concentrations of 4 times the MIC. In L cell infectious system, MIC
50 and MBC
50 of rokitamycin were 0.005-0.0125μg/ml and 0.05-0.1μg/ml respectively. The ratios of MBC
50/MIC
50 were 1-2 Ratios of leukomycin, josamycin, and erythromycin were 0.05-0.1μg/ml, 0.05-0.2μg/m1 and 0.050-0.1μg/ml respectively. The MBC
50 of these drugs were 0.2-0.4μg/ml, 0.8-1.6μg/ml, 0.8-1.6 pg/ml. Ratios of MBCv/MIC
50 were 2-8, 4-32, 8-32.
These accumulated results suggest that rokitamycin possesses potent antimycoplasmal activity except macrolide resistant mutants of
M. pneumoniae, and rokitamycin could be a promising antimycoplasmal drug for the treatment of mycoplasmal infections.
View full abstract